American Journal of Respiratory Medicine

, Volume 1, Issue 3, pp 201–209 | Cite as

Intrapulmonary Pharmacokinetics of Antibacterial Agents

Implications for Therapeutics
  • Loretta M. Chiu
  • Guy W. Amsden
Review Article


The idea of studying the pharmacokinetics and pharmacodynamics of antibacterials in order to predict their efficacy has long been of interest. Traditionally, serum drug concentrations have been evaluated against the minimum inhibitory concentration (MIC) of a given pathogen; however, infection site-specific data continue to gain interest from clinicians. Despite methodological limitations, progress in techniques has improved the clinical significance of data generated. Rather than using tissue homogenates which fail to differentiate between interstitial and intracellular concentrations, newer collection techniques focus on sampling of matrices that allow for this differentiation. These collection techniques now allow one to accurately describe β-lactam and aminoglycoside interstitial penetrations, as well as, the interstitial and phagocytic concentrations of macrolides and fluoroquinolones. By using these specific data and the MICs of infecting pathogens, it is hoped that conclusions can be drawn by a clinician as to the appropriateness of the choice of an antibacterial.


Minimum Inhibitory Concentration Alveolar Macrophage Azithromycin Macrolides Cefixime 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors have received no funding for the preparation of this manuscript and have no conflicts of interest that are directly relevant to it.


  1. 1.
    Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–12PubMedCrossRefGoogle Scholar
  2. 2.
    Pennington JE. Penetration of antibiotics into respiratory secretions. Rev Infect Dis 1981; 3: 67–73PubMedCrossRefGoogle Scholar
  3. 3.
    Bergogne-Berezin E. Penetration of antibiotics into the respiratory tree. J Antimicrob Chemother 1981; 8: 171–4PubMedCrossRefGoogle Scholar
  4. 4.
    Saggers BA, Lawson D. Some observations on the penetration of antibiotics through mucus in vitro. J Clin Pathol 1966; 19: 313–7PubMedCrossRefGoogle Scholar
  5. 5.
    Saggers BA, Lawson D. In vivo penetration of antibiotics into sputum in cystic fibrosis. Arch Dis Child 1968; 43: 404–9PubMedCrossRefGoogle Scholar
  6. 6.
    Valcke Y, Pauwies R, Van Der Straeten M. Pharmacokinetics of antibiotics in the lungs. Eur Respir J 1990; 3: 715–22PubMedGoogle Scholar
  7. 7.
    Biagi GL, Guerra MC, Barbaro AM, et al. Influence of lipophilic character on the antibacterial activity of cephalosporins and penicillins. J Med Chem 1970; 13: 511–6PubMedCrossRefGoogle Scholar
  8. 8.
    Barza M, Cuchural G. General principles of antibiotic tissue penetration. J Antimicrob Chemother 1985; 15Suppl A: 59–75PubMedCrossRefGoogle Scholar
  9. 9.
    Ogren S, Cars O. Importance of drug-protein interactions and protein concentrations for antibiotic levels in serum and tissue fluid. Scand J Infect Dis 1985; Suppl. 44: 34–40Google Scholar
  10. 10.
    Bergan T, Engeset A, Olszewski W. Does serum protein binding inhibit tissue penetration of antibiotics? Rev Infect Dis 1987; 9(4): 713–8PubMedCrossRefGoogle Scholar
  11. 11.
    Ryan DM, Cars O, Hoffstedt B. The use of antibiotic serum levels to predict concentrations in tissues. Scand J Infect Dis 1986; 18: 381–8PubMedCrossRefGoogle Scholar
  12. 12.
    Honeybourne D, Baldwin DR. The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother 1992; 30: 249–60PubMedCrossRefGoogle Scholar
  13. 13.
    Cohen GM. Pulmonary metabolism of foreign compounds: its role in metabolic activation. Environ Health Perspect 1990; 85: 31–41PubMedCrossRefGoogle Scholar
  14. 14.
    Nix DE. Intrapulmonary concentrations of antimicrobial agents. Infect Dis Clin North Am 1998; 12: 631–46PubMedCrossRefGoogle Scholar
  15. 15.
    Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992; 36: 1176–80PubMedCrossRefGoogle Scholar
  16. 16.
    Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 1992; 36: 1171–5PubMedCrossRefGoogle Scholar
  17. 17.
    Cook PJ, Andrews JM, Woodcock J, et al. Concentration of amoxicillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax 1994; 49: 1134–8PubMedCrossRefGoogle Scholar
  18. 18.
    Amsden GW, Ballow CH, Forrest A. Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects. Clin Drug Invest 1997; 13: 152–61CrossRefGoogle Scholar
  19. 19.
    Rodvold KA, Gotfried MH, Danziger LH, et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997; 41: 1399–402PubMedGoogle Scholar
  20. 20.
    Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996; 40: 2375–9PubMedGoogle Scholar
  21. 21.
    Rodvold KA, Danziger LH. Intrapulmonary concentrations of clarithromycin and azithromycin: impact of differences in methodology on the variability of results [abstract]. Proceedings of the Sixth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; 2002 Jan 23–25; Bologna, 129. Atlanta (GA): Wallace Communications Inc., 2002Google Scholar
  22. 22.
    Ramphal R, Lhermitte M, Filliat M, et al. The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum. J Antimicrob Chemother 1988; 22: 483–90PubMedCrossRefGoogle Scholar
  23. 23.
    Muller-Serieys C, Bancal C, Dombret MC, et al. Penetration of cepodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients. Antimicrob Agents Chemother 1992; 36: 2099–103PubMedCrossRefGoogle Scholar
  24. 24.
    Baldwin DR, Andrews JM, Ashby JP, et al. Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax 1990; 45: 401–2PubMedCrossRefGoogle Scholar
  25. 25.
    Nix DE, Goodwin D, Peloquin CA, et al. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother 1991; 35: 1953–9PubMedCrossRefGoogle Scholar
  26. 26.
    Muller-Siereys C, Bergogne-Berezin E, Rowan C, et al. Imipenem penetration into bronchial secretions. J Antimicrob Chemother 1987; 20: 618–9CrossRefGoogle Scholar
  27. 27.
    Marlin GE, Burgess KR, Burgoyne J, et al. Penetration of piperacillin into bronchial mucosa and sputum. Thorax 1981; 36: 774–80PubMedCrossRefGoogle Scholar
  28. 28.
    Mazzei T, Novelli A, De Lalla F, et al. Tissue penetration and pulmonary disposition of tobramycin. J Chemother 1995; 7: 363–70PubMedGoogle Scholar
  29. 29.
    Carcas AJ, Garcia-Satue JL, Zapater P, et al. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther 1999; 65: 245–50PubMedCrossRefGoogle Scholar
  30. 30.
    Lamer C, De Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37: 281–6PubMedCrossRefGoogle Scholar
  31. 31.
    Yao JDC, Moellering RC. Antimicrobial agents: glycopeptides and lipopeptides. In: Balows A, Hausler WJ, Herrmann KL, et al., editors. Manual of clinical microbiology. 5th ed. Washington, DC: American Society for Microbiology, 1991: 1076–7Google Scholar
  32. 32.
    Freeman CD, Nightingale CH, Nicolau DP, et al. Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. Antimicrob Agents Chemother 1994; 38: 2449–51PubMedCrossRefGoogle Scholar
  33. 33.
    Baldwin DR, Wise R, Andrews JM, et al. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990; 3: 886–90PubMedGoogle Scholar
  34. 34.
    Olsen KM, San Pedro GS, Gann LP, et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996; 40: 2582–5PubMedGoogle Scholar
  35. 35.
    Honeybourne D, Kees F, Andrews JM, et al. The levels of clarithromycin and its 14-hydroxy metabolite in the lung. Eur Respir J 1994; 7: 1275–80PubMedCrossRefGoogle Scholar
  36. 36.
    Decre D, Bergogne-Berezin E. Pharmacokinetics of quinolones with special reference to the respiratory tree. J Antimicrob Chemother 1993; 31: 331–43PubMedCrossRefGoogle Scholar
  37. 37.
    Honeybourne D, Andrews JM, Ashby JP, et al. Evaluation of the penetration of ciprofloxacin and amoxicillin into the bronchial mucosa. Thorax 1988; 43: 715–9PubMedCrossRefGoogle Scholar
  38. 38.
    Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119: 1114–22PubMedCrossRefGoogle Scholar
  39. 39.
    Andrews JM, Honeybourne D, Brenwald NP, et al. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administrations of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 39: 797–802PubMedCrossRefGoogle Scholar
  40. 40.
    Amsden GW. Pneumococcal macrolide resistance: myth or reality? J Antimicrob Chemother 1999; 44: 1–6PubMedCrossRefGoogle Scholar
  41. 41.
    Kashuba ADM, Bertino Jr JS, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by Gram-negative organisms. Antimicrob Agents Chemother 1998; 42: 1842–4PubMedGoogle Scholar
  42. 42.
    Amsden GW, Graci DM, Cabelus LJ, et al. A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections. Chest 1999; 116: 115–9PubMedCrossRefGoogle Scholar
  43. 43.
    Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 811–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.The Clinical Pharmacology Research Center and Department of Adult and Pediatric MedicineBassett HealthcareCooperstownUSA

Personalised recommendations